biote (NASDAQ:BTMD) and Henry Schein (NASDAQ:HSIC) Financial Survey

Henry Schein (NASDAQ:HSIC) and biote (NASDAQ:BTMD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 0.9% of Henry Schein shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Henry Schein and biote, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1	6	8	0	2.47
biote	1	1	1	1	2.50

Henry Schein currently has a consensus target price of $92.27, suggesting a potential upside of 2.78%. biote has a consensus target price of $2.50, suggesting a potential upside of 70.07%. Given biote’s stronger consensus rating and higher possible upside, analysts clearly believe biote is more favorable than Henry Schein.

Profitability

This table compares Henry Schein and biote’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.96%	15.97%	5.56%
biote	3.19%	-22.33%	12.10%

Valuation and Earnings

This table compares Henry Schein and biote”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18 billion	0.76	$398.00 million	$3.43	26.17
biote	$192.22 million	0.27	$27.05 million	$0.11	13.36

Henry Schein has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Henry Schein has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, biote has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Summary

Henry Schein beats biote on 8 of the 15 factors compared between the two stocks.

About Henry Schein

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.